An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2

In this retrospective study, a cohort of 67 subjects vaccinated with AZD1222 was retrospectively observed. Consistently with published findings, no serious adverse event was reported, and all adverse events reported (fever, muscle ache and/or pain in the site of injection) had resolved by day 8. Of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerino, Pellegrino, Coppola, Annachiara, Pierri, Biancamaria, Volzone, Palmiero, Bruzzese, Dario, Pierri, Andrea, Ferro, Amedeo, Schiavi, Daniela, Coppola, Antonio, Miniero, Stefano, Atripaldi, Luigi, Pirozzi, Caterina, Rusciano, Pasquale, Macri, Alessandra, Boenzi, Rita, Sale, Silvia, Brambilla, Gianfranco, Buonerba, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216649/
https://www.ncbi.nlm.nih.gov/pubmed/34290884
http://dx.doi.org/10.2144/fsoa-2021-0064
Descripción
Sumario:In this retrospective study, a cohort of 67 subjects vaccinated with AZD1222 was retrospectively observed. Consistently with published findings, no serious adverse event was reported, and all adverse events reported (fever, muscle ache and/or pain in the site of injection) had resolved by day 8. Of note, some citizens were prescribed low-dose aspirin and even heparin for thrombosis prevention. We also found variations in laboratory test results (full blood count and chemistry) on day 1 compared with day 8. Physicians should be aware that no prevention therapy for thrombosis is currently recommended, given the very low incidence of this side effect. Additional studies are warranted to interpret our findings.

Ejemplares similares